Development and evaluation of nitrendipine loaded solid lipid nanoparticles: Influence of wax and glyceride lipids on plasma pharmacokinetics

International Journal of Pharmaceutics

Volumn 335, Issue 1-2, 2007, Pages 167-175

  Kumar, Venishetty Vinay ^a,b   Chandrasekar, Durairaj ^b   Ramakrishna, Sistla ^b   Kishan, Veerabrahma ^a   Rao, Yamsani Madhusudan ^a   Diwan, Prakash Vamanrao ^b  

^a KAKATIYA UNIVERSITY   (India)

^b INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Bioavailability; Intraduodenal; Lipophilic; Nitrendipine; Pharmacokinetics; Solid lipid nanoparticles

Indexed keywords

CETYLPALMITATE; GLYCEROL STEARATE; NITRENDIPINE; PALMITIC ACID DERIVATIVE; POLOXAMER; SOLID LIPID NANOPARTICLE; TRIPALMITIN; UNCLASSIFIED DRUG;

ACIDITY; ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIFFUSION; DISPERSION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; DRUG SYNTHESIS; FIRST PASS EFFECT; IN VITRO STUDY; LIPOPHILICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MELTING POINT; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; TEMPERATURE DEPENDENCE; ULTRASOUND; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL AVAILABILITY; CALCIUM CHANNEL BLOCKERS; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; GLYCERIDES; INTUBATION, GASTROINTESTINAL; LIPIDS; MALE; NANOPARTICLES; NITRENDIPINE; PALMITATES; PARTICLE SIZE; POLOXAMER; RATS; RATS, WISTAR; SOLUBILITY; SURFACE-ACTIVE AGENTS; TECHNOLOGY, PHARMACEUTICAL; TRIGLYCERIDES; WAXES;

EID: 33947572663     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.11.004     Document Type: Article

References (17)

1. Bargoni A., Cavalli R., and Caputo O. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm. Res. 15 (1998) 745-750
2. Cavalli R., Bargoni A., Podio V., and Muntoni E. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J. Pharm. Sci. 92 (2003) 1085-1094
3. Charman W.N., and Porter C.J.H. Lipophilic prodrugs designed for intestinal lymphatic transport. Adv. Drug Deliv. Rev. 19 (1996) 149-169
4. Driscoll M.C. Lipid based formulations for intestinal lymphatic delivery. Eur. J. Pharm. Sci. 15 (2002) 405-415
5. Harivardhan Reddy L., and Murthy R.S.R. Etoposide loaded nanoparticles made from glyceride lipids: formulation, characterization, in vitro drug release and stability evaluation. AAPS PharmSciTech. 6 (2005) E158-E166
6. Holm R., Mullertz A., Pedersen G.P., and Christensen H.G. Comparison of the lymphatic transport of halofantrine administered in disperse systems containing three different unsaturated fatty acids. Pharm. Res. 18 (2001) 1299-1304
7. Jenning V., and Gohla S. Comparison of wax and glycerides solid lipid nanoparticles. Int. J. Pharm. 196 (2000) 219-222
8. Manjunath K., and Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Control. Release 107 (2005) 215-228
9. Mansbach C.M., and Nevin P. Intracellular movement of triacylglycerols in intestine. J. Lipid Res. 39 (1998) 963-968
10. Mehnert W., and Mader K. Solid lipid nanoparticles production, characterization and applications. Adv. Drug Deliv. Rev. 47 (2001) 165-196
11. Muller R.H., Mader K., and Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm. 50 (2000) 161-177
12. Nordskog B.K., Phan C.T., Nutting D.F., and Tso P. An examination of the factors affecting intestinal lymphatic transport of dietary lipids. Adv. Drug Deliv. Rev. 50 (2001) 21-44
13. Parfitt K. Martindale. The Complete Drug Reference, 32 (1999), Pharmaceutical Press, London, UK
14. Porter C.J.H., and Charman W.N. Intestinal lymphatic drug uptake: an update. Adv. Drug Deliv. Rev. 50 (2001) 61-80
15. Ros E. Intestinal absorption of triglyceride and cholesterol, dietary and pharmacological inhibition to reduce cardiovascular risk. Atherosclerosis 151 (2000) 357-379
16. Venkateswarlu V., and Manjunath K. Preparation characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J. Control. Release 95 (2004) 627-638
17. Wissing S.A., Kayser O., and Muller R.H. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 56 (2004) 1257-1272